Array BioPharma, Inc. has entered a strategic collaboration with Celgene Corp. for its preclinical development program targeting a novel inflammation pathway. Array will receive an upfront payment of $11 million and Celgene will have an exclusive option to license multiple clinical development candidates. Array is eligible to receive potential milestone payments of as much as $376 million based certain development, regulatory and sales objectives. Array is also entitled to receive royalties on s...